Stonekeep Investments LLC Invests $313,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Stonekeep Investments LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 15,517 shares of the company’s stock, valued at approximately $313,000.

Other hedge funds have also added to or reduced their stakes in the company. Arizona State Retirement System boosted its holdings in Hims & Hers Health by 3.0% in the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after purchasing an additional 1,173 shares during the period. Belpointe Asset Management LLC boosted its stake in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after buying an additional 1,205 shares during the period. Victory Capital Management Inc. grew its position in Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after buying an additional 1,212 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the period. Finally, Swiss National Bank raised its holdings in Hims & Hers Health by 0.7% in the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after acquiring an additional 2,000 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Trading Down 5.4 %

Hims & Hers Health stock opened at $13.65 on Monday. The stock has a 50-day moving average price of $18.36 and a two-hundred day moving average price of $16.86. Hims & Hers Health, Inc. has a 12 month low of $5.65 and a 12 month high of $25.74. The company has a market capitalization of $2.93 billion, a PE ratio of -1,365.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. During the same quarter last year, the business earned ($0.03) EPS. The firm’s quarterly revenue was up 51.8% on a year-over-year basis. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Citigroup cut Hims & Hers Health from a “buy” rating to a “neutral” rating and raised their price target for the stock from $16.00 to $20.00 in a research report on Wednesday, May 22nd. TD Cowen raised their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Truist Financial upped their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $20.29.

Insider Activity

In related news, COO Melissa Baird sold 11,749 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $14.65, for a total value of $172,122.85. Following the sale, the chief operating officer now owns 585,800 shares of the company’s stock, valued at $8,581,970. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, COO Melissa Baird sold 11,749 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $14.65, for a total value of $172,122.85. Following the sale, the chief operating officer now directly owns 585,800 shares in the company, valued at $8,581,970. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 45,755 shares of the stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $22.97, for a total transaction of $1,050,992.35. Following the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $769,540.94. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 753,292 shares of company stock valued at $13,557,329. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.